ICON Public (NASDAQ:ICLR) Price Target Cut to $265.00 by Analysts at JPMorgan Chase & Co.

ICON Public (NASDAQ:ICLR) had its price objective lowered by JPMorgan Chase & Co. from $280.00 to $265.00 in a report published on Monday,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the medical research company’s stock.

Several other equities research analysts also recently issued reports on ICLR. Robert W. Baird lowered their price target on ICON Public from $249.00 to $225.00 and set a “neutral” rating for the company in a report on Wednesday, November 20th. Royal Bank of Canada reiterated an “outperform” rating and set a $263.00 target price on shares of ICON Public in a report on Wednesday, January 15th. Redburn Atlantic assumed coverage on shares of ICON Public in a research note on Monday, October 14th. They set a “neutral” rating and a $311.00 price target for the company. The Goldman Sachs Group lowered their target price on ICON Public from $370.00 to $280.00 and set a “buy” rating on the stock in a research report on Friday, October 25th. Finally, TD Cowen decreased their target price on shares of ICON Public from $369.00 to $285.00 and set a “buy” rating for the company in a research note on Friday, October 25th. Four equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, ICON Public presently has a consensus rating of “Moderate Buy” and an average price target of $285.75.

ICON Public Trading Down 1.8 %

ICLR opened at $195.51 on Monday. The firm’s fifty day moving average is $208.91 and its two-hundred day moving average is $257.50. The firm has a market cap of $16.13 billion, a PE ratio of 21.80, a price-to-earnings-growth ratio of 1.79 and a beta of 1.20. ICON Public has a twelve month low of $183.38 and a twelve month high of $347.72. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.34 and a current ratio of 1.34.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Transcend Capital Advisors LLC bought a new stake in shares of ICON Public during the 4th quarter valued at approximately $229,000. FDx Advisors Inc. grew its stake in shares of ICON Public by 13.6% during the fourth quarter. FDx Advisors Inc. now owns 3,527 shares of the medical research company’s stock worth $740,000 after buying an additional 422 shares during the last quarter. Kornitzer Capital Management Inc. KS increased its holdings in shares of ICON Public by 40.6% during the fourth quarter. Kornitzer Capital Management Inc. KS now owns 97,102 shares of the medical research company’s stock worth $20,363,000 after buying an additional 28,050 shares in the last quarter. Sierra Ocean LLC bought a new position in shares of ICON Public in the 4th quarter valued at $29,000. Finally, Entropy Technologies LP boosted its holdings in shares of ICON Public by 472.2% during the 4th quarter. Entropy Technologies LP now owns 6,174 shares of the medical research company’s stock valued at $1,295,000 after acquiring an additional 5,095 shares in the last quarter. Institutional investors and hedge funds own 95.61% of the company’s stock.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.